Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancer
The latest plain language summary in Future Oncology provides an overview of the results of the CROWN study that compared lorlatinib with crizotinib in people with previously untreated ALK-positive advanced non-small cell lung cancer.
Read the full PLSP here.
The original article, called ‘First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer’ was published in the New England Journal of Medicine and can be read here.